Naratuximab manufacturers
- Naratuximab
-
- $629.00
-
2026-07-10
- CAS:1622327-39-2
- Purity: 95.00%
- Supply Ability: 10g
|
| | Naratuximab Basic information |
| Product Name: | Naratuximab | | Synonyms: | Naratuximab;Research Grade Naratuximab(DHC85102);Research Grade Naratuximab;Naratuximab (anti-CD37) | | CAS: | 1622327-39-2 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Naratuximab Structure]() |
| | Naratuximab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Naratuximab Usage And Synthesis |
| Uses | Naratuximab (Anti-TSPAN26/CD37 Reference Antibody (naratuximab)) is a humanized monoclonal antibody that binds CD37 (TSPAN26). Naratuximab can be used to synthesize an ADC compound, Naratuximab emtansine[1]. | | References | [1] Stuart W Hicks, et al. The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models. Neoplasia. 2017 Sep;19(9):661-671. DOI:10.1016/j.neo.2017.06.001 |
| | Naratuximab Preparation Products And Raw materials |
|